An observational study in Sarcopenia, Kidney Transplantation and Muscle Wasting, sponsored by Sichuan Provincial People's Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-26.
Sponsored by Sichuan Provincial People's Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Sarcopenia with a site in China — 47 open to participants now, 52 under way, 4 of them phase 3. Sarcopenia · China.
Among the 83 studies in Sarcopenia with a site in China, this one is the 28th largest by planned enrollment of the 31 observational ones that give a count, is one of 16 that started in 2026, is one of 31 observational ones, reaches primary completion later than 29 of the 51 other live ones, and was the 69th registered.
1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.
Browse Sarcopenia studies →47 of the 83 studies in Sarcopenia with a site in China are open now. Recruiting first, the newest first:
Shanghai Yueyang Integrated Medicine Hospital · Sites in China
Ages 60–90
Hangzhou PhecdaMed Co., Ltd. · Sites in China
Ages 60+
GuangZhou Cellgenes Biotechnology Co., Ltd. · Sites in China
Ages 50–85
Peking Union Medical College Hospital · Sites in China
Ages 18+
China Medical University, China · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 4 · Phase 4 3
First in 2012; this study’s year is marked. 16 started in 2026.
This study's planned enrollment of 140 is above the median of 120 across 455 observational studies indexed under Sarcopenia.
Median enrollment 110 across the 52 interventional studies, 868 across the 31 observational. Of the 25 that completed or were terminated, 1 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 83 have an industry lead sponsor. The 10 most frequent:
Sichuan Provincial People's Hospital is the lead sponsor of 78 studies on the registry; 43 are open to participants now.
Sichuan Provincial People's Hospital has 1 study filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
14 of the studies in Sarcopenia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07950150The Hong Kong Polytechnic UniversityPomegranate-Prebiotic Supplementation for Sarcopenic Obesity | 2026-12 |
| NCT07049731Weiwei MaImprovement of Skeletal and Muscle Health in Patients With Sarcopenia by Protein Powder With Resistance Exercise | 2026-12 |
| NCT07724587Ningbo Medical Center Lihuili HospitalThe Effectiveness and Safety of Combined Research on Uremic Sarcopenia | 2026-12-01 |
| NCT07059871Zhejiang HospitalA Study of Silkworm Pupa Powder Intervention in the Nutritional Status of Patients With Alzheimer's Disease. | 2026-12-30 |
| NCT07538674Shanghai Yueyang Integrated Medicine HospitalPeiyuan Guben Tongluo Ointment for Elderly Sarcopenia | 2027-03-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 83 studies in Sarcopenia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single-center prospective observational study designed to evaluate the effectiveness of multimodal muscle ultrasound for the assessment of sarcopenia in kidney transplant recipients. Adult patients undergoing kidney transplantation will undergo both muscle ultrasound and bioelectrical impedance analysis (BIA) at predefined time points before and after transplantation.
The primary objective is to evaluate the diagnostic performance of muscle ultrasound for sarcopenia assessment, including its correlation and agreement with BIA-derived skeletal muscle index (BIA-SMI), as well as its diagnostic accuracy. Secondary objectives include describing the longitudinal changes in sarcopenia prevalence and muscle-related parameters from the pre-transplant period to 1 year after transplantation.
The study aims to provide evidence for a convenient, noninvasive, radiation-free, and reliable method for sarcopenia assessment in kidney transplant recipients.
Sarcopenia is highly prevalent among patients with end-stage renal disease and is associated with poor clinical outcomes. Although kidney transplantation may improve overall health status, perioperative stress, immunosuppressive therapy, and postoperative metabolic changes may influence muscle mass and function. Reliable assessment of sarcopenia in kidney transplant recipients remains clinically important.
Current methods for sarcopenia assessment include computed tomography (CT), dual-energy X-ray absorptiometry (DXA), and bioelectrical impedance analysis (BIA). However, CT and DXA are limited by radiation exposure, cost, and accessibility, while BIA may be affected by changes in hydration status, especially in transplant recipients. Muscle ultrasound is a portable, radiation-free, and bedside-available imaging modality that may provide a practical alternative for muscle assessment.
This prospective observational study will enroll adult kidney transplant recipients at Sichuan Provincial People's Hospital. Participants will undergo multimodal muscle ultrasound and BIA examinations at predefined perioperative time points. Ultrasound parameters will include muscle thickness, cross-sectional area, and echogenicity.
The primary study objective is to evaluate the diagnostic performance of muscle ultrasound for sarcopenia assessment using BIA-derived skeletal muscle index (BIA-SMI) as the reference standard. Correlation analysis, intraclass correlation coefficients, Bland-Altman analysis, and receiver operating characteristic (ROC) curve analysis will be performed to evaluate agreement and diagnostic accuracy.
Secondary objectives include evaluating longitudinal changes in muscle-related parameters and sarcopenia prevalence from the pre-transplant period to 1 year after kidney transplantation. Linear mixed-effects models or generalized estimating equations will be used to analyze temporal trends.
This study aims to establish muscle ultrasound as a practical and reliable tool for sarcopenia assessment in kidney transplant recipients and to improve understanding of perioperative muscle changes after transplantation.
Adult kidney transplant recipients undergoing perioperative sarcopenia assessment at Sichuan Provincial People's Hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult kidney transplant recipients undergoing prospective assessment of sarcopenia using multimodal muscle ultrasound and bioelectrical impedance analysis (BIA).
Diagnostic Test: Muscle Ultrasound
Multimodal muscle ultrasound assessment performed for evaluation of sarcopenia in kidney transplant recipients.
Area under the receiver operating characteristic (ROC) curve of muscle ultrasound for detecting sarcopenia using BIA-derived skeletal muscle index (BIA-SMI) as the reference standard.
Diagnostic performance of multimodal muscle ultrasound for sarcopenia assessment using BIA-derived skeletal muscle index (BIA-SMI) as the reference standard, including receiver operating characteristic (ROC) curve analysis and area under the curve (AUC).
Time frame: From baseline to 1 year after kidney transplantation
Change in Muscle Thickness Measured by Ultrasound
Longitudinal changes in muscle thickness measured by ultrasound from baseline to 1 year after kidney transplantation.
Time frame: From baseline to 1 year after kidney transplantation
Change in Muscle Cross-Sectional Area Measured by Ultrasound
Longitudinal changes in muscle cross-sectional area measured by ultrasound from baseline to 1 year after kidney transplantation.
Time frame: From baseline to 1 year after kidney transplantation
Change in Muscle Echogenicity Measured by Ultrasound
Longitudinal changes in muscle echogenicity measured by ultrasound from baseline to 1 year after kidney transplantation.
Time frame: From baseline to 1 year after kidney transplantation
Plan to share: No — Individual participant data will not be publicly available due to institutional policy and participant privacy considerations.
No publications or documents are linked to this record.
Start is estimated for May 2026; primary completion for Aug 2027, 15 months later.
Of 192 non-industry observational studies under Sarcopenia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 63. This study's planned 15 months is below that.
Counting every sponsor, half of 194 studies reached it within 26 months; a quarter within 12 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sichuan Provincial People's Hospital